Aura Biosciences, Inc. (AURA) - Q2 2026 10-Q Summary
Business Context and Reporting Period
Aura Biosciences, Inc. is a clinical-stage biotechnology company developing precision therapies for solid tumors, with a primary focus on ocular and urologic oncology. The company's lead product candidate, belzupacap sarotalocan (bel-sar), is a Virus-Like Drug Conjugate (VDC) currently in a global Phase 3 trial (CoMpass) for early choroidal melanoma. This report covers the quarterly period ended June 30, 2026.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(45.6) million | $(27.0) million | $(79.3) million | $(54.5) million |
| Operating Expenses | $48.1 million | $28.6 million | $82.9 million | $57.6 million |
| Research & Development | $30.7 million | $22.9 million | $58.7 million | $46.2 million |
| General & Administrative | $17.3 million | $5.7 million | $24.2 million | $11.4 million |
| Cash & Marketable Securities | $323.8 million (as of June 30, 2026) | |||
| Net Cash Used in Operating Activities | N/A | $(62.4) million | $(44.1) million |
Material Changes vs. Prior Period
- Capital Raise: In May 2026, the company completed a follow-on offering raising approximately $280.8 million in net proceeds. Approximately $39.0 million of these proceeds were immediately used to repurchase 6.9 million shares from Matrix Capital Management Master Fund, LP.
- Expense Increase: Operating expenses increased significantly year-over-year. R&D expenses rose due to clinical trial progression and manufacturing development for bel-sar. G&A expenses surged primarily due to stock-based compensation related to executive leadership transitions and higher professional fees.
- Investing Activities: Net cash used in investing activities was $171.1 million for the six months ended June 30, 2026, driven by the purchase of marketable securities ($256.0 million) following the capital raise, partially offset by maturities.
Guidance, Outlook, and Risks
- Clinical Outlook: The company has completed enrollment in the pivotal Phase 3 CoMpass trial for early choroidal melanoma but does not expect topline data until the second half of 2027. Interim data from a Phase 1b/2 study in non-muscle invasive bladder cancer (NMIBC) showed encouraging results, though the company is minimizing resource allocation to this program to refocus on ocular oncology.
- Liquidity: Management believes existing cash and marketable securities ($323.8 million) are sufficient to fund operations into the first half of 2029.
- Restructuring: In August 2026 (subsequent event), the company announced a restructuring plan to streamline operations, including a workforce reduction of approximately 20%. Estimated restructuring charges are between $2.9 million and $3.2 million.
- Key Risks: The company is heavily dependent on the success of bel-sar. Risks include delays in regulatory approval, failure of clinical trials, reliance on third-party CDMOs for manufacturing, and the need for additional capital to sustain operations beyond 2029.
Investor Verification Checklist
- Cash Runway: Verify the $323.8 million cash position and the assumption that it funds operations through H1 2029, considering the recent 20% workforce reduction.
- Capital Allocation: Confirm the use of $39.0 million from the May 2026 offering for the Matrix Capital share repurchase and the impact on dilution.
- Clinical Timeline: Monitor the timeline for the Phase 3 CoMpass trial topline data (expected H2 2027) and any potential delays.
- Restructuring Costs: Track the actual restructuring charges incurred in Q3 2026 against the estimated $2.9M–$3.2M range.
- Stock-Based Compensation: Review the impact of the new CEO's inducement award plan and other equity grants on future G&A expenses.